恩替卡韦治疗慢性乙型肝炎肝纤维化的临床观察

目的通过观察恩替卡韦治疗慢性乙型肝炎对肝脏组织病理和肝纤维化指标的影响,评估其抗肝纤维化的疗效.方法选取慢性乙型肝炎患者81例,随机分为两组,治疗组41例,恩替卡韦0.5 mg,1次/d,口服;对照组40例,给予常规护肝药物治疗,疗程均为48周.观察治疗后肝纤维化指标和肝活组织病理改变,并进行比较.结果治疗后两组患者肝纤维化指标均明显下降,治疗组比对照组下降更为显著,肝组织学评估结果有显著改善（P〈0.05）.结论恩替卡韦治疗慢性乙型肝炎肝纤维化临床疗效确切,无严重不良反应.

Clinical Observation on Hepatic Fibrosis of Chronic Hepatitis B Treated with Entecavir

Objective To evaluate the clinical therapeutic effect of entecavir on hepatic fibrosis serum indicators and liver pathology in chronic hepatitis B. Methods A total of 81 patients with chronic hepatitis B were randomly divided into two groups：41 cases in treatment group were treated with 0. 5mg entecavir,one time per day,40 cases in control group were given the conventional liver drug therapy,and all patients were treated for 48 weeks. After the treatment,the liver fibrosis indicators and liver histopathological changes were observed and compared. Results Levels of serum hepatic fibrosis indicators of the patients in the two groups were both significantly lower,but the decrease of them in treatment group was more significantly compared with that in control group;the liver histopathological changes were significantly improved after the treatment（ P〈0. 05）.Conclusion Entecavir has a clear clinical therapeutic effect on hepatic fibrosis of chronic hepatitis B and no obvious adverse reactions.